

Paul A Gurbel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5010605/paul-a-gurbel-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354
papers

20,473
citations

62
h-index

137
g-index

394
ext. papers

23,287
ext. citations

6.3
avg, IF

6.54
L-index

#	Paper	IF	Citations
354	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. <i>Nature Reviews Cardiology</i> , 2022 ,	14.8	16
353	Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 53, 363	5.1	3
352	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1	
351	Peri-procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making 2022 , 483-490		
350	Monitoring and Reversal of Anticoagulation and Antiplatelet Agents 2022 , 491-502		
349	Is clopidogrel as the P2Y inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?. <i>EuroIntervention</i> , 2021 , 17, e865-e866	3.1	
348	Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography.. <i>TH Open</i> , 2021 , 5, e570-e576	2.7	0
347	Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2021 , 6, 749-761	8.7	0
346	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021 ,	1.4	1
345	Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 902-904	5.1	8
344	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4638-4651	9.5	21
343	Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice: Translational Implications for Human Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, e265-e279	9.4	1
342	First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab274	1	5
341	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 992-998	5.1	3
340	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 272-280	5.1	
339	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. <i>Advances in Therapy</i> , 2021 , 38, 3911-3923	4.1	10
338	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1

337	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 602-611	2.7	7
336	An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 40-50	2.6	1
335	Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B and agonist-induced platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 260-264	5.1	4
334	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 422-432	7	47
333	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 454-465	5.1	6
332	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021 , 51, 202-221	2.2	5
331	Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1376-1386	7	6
330	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
329	Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1277-1286	15.1	2
328	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 544-549	1	4
327	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. <i>Platelets</i> , 2021 , 1-11	3.6	1
326	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 957-970	3	0
325	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020 , 29, 100647	11.3	9
324	Can an Old Ally Defeat a New Enemy?. <i>Circulation</i> , 2020 , 142, 315-317	16.7	8
323	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1067-1077	6.1	12
322	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020 , 16, 373-384	1.3	4
321	Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. <i>Circulation</i> , 2020 , 142, 150-160	16.7	44
320	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , 2020 , 395, 866-867	40	

319	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. <i>Future Cardiology</i> , 2020 , 16, 69-75	1.3	1
318	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 484-498	5.1	3
317	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 578-586	15.1	39
316	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 449-456	7	5
315	Assessing platelet reactivity after drug eluting stent implantation: state of the art. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 17-24	2.5	
314	The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 969-981	5.1	4
313	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 243-248	8.5	2
312	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020 , 10, 6169	4.9	8
311	Abstract 16676: Heightened Platelet Function: An Unrecognized Component of the Covid Hypercoagulability State. <i>Circulation</i> , 2020 , 142,	16.7	1
310	Ion channel inhibition against COVID-19: A novel target for clinical investigation. <i>Cardiology Journal</i> , 2020 , 27, 421-424	1.4	7
309	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020 , 27, 661-676	1.4	4
308	Antiplatelet Agent Choice and Platelet Function Testing in CKD 2020 , 103-118		
307	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. <i>Anesthesiology</i> , 2020 , 133, 1263-1276	4.3	5
306	Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 173-176	5.1	8
305	TEG [®] 6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care. <i>Platelets</i> , 2020 , 31, 932-938	3.6	7
304	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 33-47	5.9	5
303	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 3132-3140	9.5	24
302	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid. <i>Circulation</i> , 2020 , 142, 1305-1307	16.7	4

301	Meta-Analysis of the Usefulness of Therapeutic Hypothermia After Cardiac Arrest. <i>American Journal of Cardiology</i> , 2020 , 133, 48-53	3	5
300	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020 , 41, 3533-3545	9.5	37
299	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2990-3003	9.4	5
298	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1851-1865	4	14
297	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1594-1596	7	18
296	Bioprosthetic Valve Thrombosis: Insights from Transcatheter and Surgical Implants. <i>Structural Heart</i> , 2020 , 4, 382-388	0.6	2
295	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1188-1196	19	40
294	Relation of High Lipoprotein(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020 , 37, 4568-4584	4.1	4
293	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 23-35	15.4	8
292	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019 , 381, 2032-2042	59.2	395
291	"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 192-199	5.1	10
290	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 373-381	5.1	8
289	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019 , 139, 2170-2185	16.7	49
288	Phosphodiesterase Inhibitors 2019 , 979-989		1
287	Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 275-278	4.6	1
286	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1521-1537	5	189
285	High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. <i>Arquivos Brasileiros De Cardiologia</i> , 2019 , 113, 357-363	1.2	0
284	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019 , 64, 166-179	10.6	17

283	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 16-30	5.1	10
282	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 413-421	3.8	11
281	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 264-273	7	2
280	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 653-665	4	13
279	Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 864-872	7	9
278	Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1368-1380	9.4	27
277	Selection of P2Y Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 460-470	8.5	7
276	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018 , 198, 152-159	4.9	19
275	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 469-476	5.1	9
274	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1322-1329	3	2
273	Cangrelor for the treatment of patients with Arterial Thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1389-1398	4	3
272	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1131-1140	7	6
271	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1277-1286	5	7
270	Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 459-476	3.3	20
269	Percutaneous Coronary Intervention: Adjunctive Pharmacology 2018 , 161-180		
268	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. <i>Atherosclerosis</i> , 2018 , 268, 55-62	3.1	3
267	Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 18-26	5.1	3
266	Thromboembolism after WATCHMAN in a clopidogrel non-responder: A case for concern?. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 200-202	2.7	

265	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. <i>Circulation</i> , 2018 , 138, 2145-2159	16.7	23
264	The potential of genotype-guided antiplatelet therapy: promises and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018 , 3, 371-377	1.6	
263	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 437-445	5.1	44
262	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 221-234	6.4	29
261	Bleeding and thrombosis associated with ventricular assist device therapy. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 1164-1173	5.8	57
260	GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. <i>Lancet, The</i> , 2017 , 389, 1773-1775	40	10
259	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 123-131	4	5
258	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017 , 136, 1955-1975	16.7	215
257	Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 911-922	7	10
256	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1607-1617	5	21
255	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 223-233	5.1	3
254	The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. <i>American Journal of Cardiovascular Drugs</i> , 2017 , 17, 109-121	4	4
253	Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. <i>Platelets</i> , 2017 , 28, 187-193	3.6	1
252	Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. <i>Clinical Cardiology</i> , 2017 , 40, 1352-1356	3.3	36
251	Monitoring of Antiplatelet Therapy 2017 , 671-679		1
250	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	2
249	Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2364	5	
248	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. <i>Heart</i> , 2016 , 102, 882-92	5.1	1

247	Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2016 , 113, 40-45	2.8	14
246	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 2010-2017	2.7	28
245	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1361-1370	2.5	3
244	Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2016 , 29, 168-78	1.8	12
243	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 779-91	2.5	2
242	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 394-403	5.1	3
241	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 936-947	15.1	32
240	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 189-97	9.4	71
239	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , 2016 , 12, 45-58	1.3	10
238	To stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?. <i>Journal of Thoracic Disease</i> , 2016 , 8, E578-80	2.6	
237	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 844-55	7	26
236	Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 979-92	7	10
235	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016 , 5, 2048004016652514	1.1	5
234	Peri-procedural Platelet Function Testing in Risk Stratification and Clinical Decision Making 2016 , 453-458		
233	Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group. <i>JACC Basic To Translational Science</i> , 2016 , 1, 73-86	8.7	34
232	Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 724-5	3.8	8
231	Platelet-Mediated Thrombosis: From Bench to Bedside. <i>Circulation Research</i> , 2016 , 118, 1380-91	15.7	36
230	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. <i>Platelets</i> , 2016 , 27, 642-649	3.6	101

229	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016 , 118, 1941-1947	3	12
228	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCElERated Inhibition of Platelet Aggregation, Inflammation and	3.2	11
227	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1762-71	9.5	218
226	Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. <i>American Journal of Cardiology</i> , 2015 , 115, 1204-11	3	14
225	Novel antiplatelet agents in cardiovascular medicine. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015 , 17, 383	2.1	3
224	Platelet activation and pneumonia: is soluble p-selectin the right marker?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1492-3	15.1	3
223	P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1149-65	4	12
222	Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. <i>American Journal of Cardiology</i> , 2015 , 115, 716-23	3	27
221	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. <i>Platelets</i> , 2015 , 26, 608-9	3.6	1
220	Vorapaxar in the secondary prevention of atherothrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1293-305	2.5	9
219	Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001683	6	47
218	Current antiplatelet treatment strategy in patients with diabetes mellitus. <i>Diabetes and Metabolism Journal</i> , 2015 , 39, 95-113	5	20
217	G-protein-coupled receptors signaling pathways in new antiplatelet drug development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 500-12	9.4	53
216	Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score. <i>Blood</i> , 2015 , 126, 3445-3445	2.2	2
215	Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. <i>JACC: Heart Failure</i> , 2014 , 2, 1-14	7.9	40
214	Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1500-9	15.1	78
213	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014 , 168, 76-87.e1	4.9	19
212	Cangrelor 2014 , 180-192		

211	Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention 2014 , 207-219		
210	Shear Stress-Based Platelet Function Tests 2014 , 92-101		
209	Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. <i>American Heart Journal</i> , 2014 , 168, 530-6	4.9	36
208	Elinogrel 2014 , 173-179		
207	Eptifibatide 2014 , 142-149		
206	Vasodilator-Stimulated Phosphoprotein (VASP) Assay 2014 , 58-64		
205	Aspirin Resistance 2014 , 277-284		
204	Other Drug Interactions with Clopidogrel 2014 , 306-313		
203	VerifyNow P2Y12 and Plateletworks Assays 2014 , 65-81		
202	Resistance to antiplatelet drugs: what progress has been made?. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2553-64	4	28
201	Tratamiento antiagregante plaquetario personalizado. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 480-487.5		8
200	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. <i>International Journal of Cardiology</i> , 2014 , 174, 129-32	3.2	2
199	Update: Acute coronary syndromes (V). Personalized antiplatelet therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 480-7	0.7	1
198	Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 943-50	7	13
197	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 589-97	7	23
196	PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy. <i>Circulation Journal</i> , 2014 , 78, 2563	2.9	1
195	Unravelling the smokersParadox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y ₁₂ inhibitors. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1187-90	7	10
194	Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 713-24	7	16

193	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 323-31	7	7
192	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1198-208	7	6
191	Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014 , 21, 1121-39	4	3
190	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 645-53	3.8	4
189	Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. <i>Journal of the American Heart Association</i> , 2014 , 3, e001167	6	14
188	Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome". <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 273	6	1
187	Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. <i>Stroke</i> , 2014 , 45, 492-503	6.7	53
186	Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2013 , 158, 261-70	8	115
185	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. <i>American Heart Journal</i> , 2013 , 166, 95-103	4.9	13
184	Cigarette smoking and clopidogrel interaction. <i>Current Cardiology Reports</i> , 2013 , 15, 361	4.2	8
183	What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. <i>Lancet, The</i> , 2013 , 382, 633-43	40	15
182	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet, The</i> , 2013 , 382, 614-23	40	606
181	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 607-614	1.4	1
180	Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 577-83	15.1	66
179	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. <i>American Heart Journal</i> , 2013 , 165, 176-82	4.9	6
178	Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring 2013 , 45-112		2
177	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2261-73	15.1	693
176	Pharmacology of antiplatelet agents. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 371	6	21

175	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1259-67	2.5	5
174	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1547-56	2.5	4
173	Thienopyridine efficacy and cigarette smoking status. <i>American Heart Journal</i> , 2013 , 165, 693-703	4.9	9
172	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013 , 168, 427-35	3.2	3
171	Monitoring of Antiplatelet Therapy 2013 , 603-633		2
170	The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 505-12	15.1	104
169	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 447-62	2.5	16
168	High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. <i>BioMed Research International</i> , 2013 , 2013, 928271	3	9
167	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. <i>Future Cardiology</i> , 2013 , 9, 785-97	1.3	3
166	Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. <i>Platelets</i> , 2013 , 24, 166-9	3.6	12
165	Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 184-92		80
164	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 1-8	1.9	107
163	Platelet reactivity and thrombogenicity in postmenopausal women. <i>Menopause</i> , 2013 , 20, 57-63	2.5	16
162	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 347-55	7	16
161	Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 808-16	7	32
160	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
159	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 12-20	7	6
158	Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. <i>Thrombosis Research</i> , 2012 , 129, 1-2	8.2	26

157	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , 2012 , 9, 373-390	3	
156	Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. <i>American Heart Journal</i> , 2012 , 164, 35-42	4.9	60
155	Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 397-409	6.3	44
154	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y ₁₂ receptor inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 1011-22	2.5	
153	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. <i>Interventional Cardiology Clinics</i> , 2012 , 1, 223-230	1.4	3
152	Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 247-54	6	25
151	Clopidogrel efficacy and cigarette smoking status. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 2495-6	27.4	42
150	Importance of potent P2Y ₁₂ receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1771-96	4	9
149	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
148	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. <i>European Heart Journal</i> , 2012 , 33, 2151-62	9.5	32
147	High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. <i>Heart</i> , 2012 , 98, 343; author reply 343-4	5.1	4
146	A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y ₁₂ inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 247-54	6	66
145	Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 261-9	6	196
144	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. <i>Circulation</i> , 2012 , 125, 1276-87; discussion 1287	16.7	85
143	We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 198; author reply 198-9	15.1	
142	The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2701-2; author reply 2702	15.1	
141	Vorapaxar: a novel protease-activated receptor-1 inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1445-53	5.9	13
140	Resistance to Antiplatelet Therapy 2011 , 1		

139	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. <i>American Heart Journal</i> , 2011 , 162, 160-5	4.9	63
138	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. <i>American Heart Journal</i> , 2011 , 161, 598-604	4.9	68
137	Do East Asians have different hypercoagulable states compared with Western population?. <i>American Heart Journal</i> , 2011 , 162, e19-20; author reply e21-2	4.9	2
136	Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS?. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 263-4	7	4
135	Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 265-71	7	26
134	Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 248-52	7	23
133	The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. <i>Journal of Cardiovascular Pharmacology</i> , 2011 , 57, 86-93	3.1	62
132	Role of ticagrelor in the treatment of coronary artery disease. <i>Clinical Investigation</i> , 2011 , 1, 429-437		
131	Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 860-6	6.1	8
130	Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 365-80	5	43
129	Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 118-20	6	6
128	Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 585-94	6	91
127	Assessment of oral antithrombotic therapy by platelet function testing. <i>Nature Reviews Cardiology</i> , 2011 , 8, 572-9	14.8	18
126	Antiplatelet Therapy 2011 , 201-221		
125	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 233-40	1.6	8
124	Combination antithrombotic therapies. <i>Circulation</i> , 2010 , 121, 569-83	16.7	96
123	Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i> , 2010 , 121, 1188-99	16.7	372
122	First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 556-66		135

121	Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". <i>Circulation</i> , 2010 , 122, e478; author reply e479	16.7	15
120	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1821-30	27.4	778
119	Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. <i>Platelets</i> , 2010 , 21, 360-7	3.6	62
118	THE INFLUENCE OF CYTOCHROME P450 2C19*2 AND*17 GENOTYPE, DIPLTYPE AND METABOLIZER STATUS ON PLATELET REACTIVITY IN PATIENTS ON MAINTENANCE CLOPIDOGREL THERAPY. <i>Journal of the American College of Cardiology</i> , 2010 , 55, A130.E1220	15.1	2
117	Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 185-93	15.1	132
116	Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1017-23	15.1	148
115	Genotyping: one piece of the puzzle to personalize antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 112-6	15.1	71
114	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 919-33	15.1	913
113	Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. <i>Thrombosis Research</i> , 2010 , 126, 384-5	8.2	4
112	Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". <i>American Heart Journal</i> , 2010 , 159, 744-8	4.9	28
111	Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. <i>American Heart Journal</i> , 2010 , 160, 346-54	4.9	123
110	Ticagrelor for the treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2251-9		21
109	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 535-44	7	35
108	Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 1040-51	2.7	22
107	The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 43-53	15.4	81
106	The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. <i>Platelets</i> , 2009 , 20, 97-104	3.6	36
105	The drug-drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009 , 180, 699-700	3.5	33
104	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 849-57	27.4	1070

103	Aspirin resistance. <i>Progress in Cardiovascular Diseases</i> , 2009 , 52, 141-52	8.5	64
102	Advances in antiplatelet therapy: agents in clinical development. <i>American Journal of Cardiology</i> , 2009 , 103, 40A-51A	3	75
101	Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. <i>American Journal of Cardiology</i> , 2009 , 103, 1546-50	3	41
100	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. <i>American Journal of Cardiology</i> , 2009 , 104, 525-30	3	46
99	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009 , 11, 22-32	2.1	11
98	Relationship between age and platelet activation in patients with stable and unstable angina. <i>Archives of Gerontology and Geriatrics</i> , 2009 , 48, 155-9	4	16
97	The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009 , 158, 784.e1-6	4.9	54
96	Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. <i>Circulation</i> , 2009 , 120, 2577-85	16.7	866
95	Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 648-57	15.1	55
94	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 989-1004	5.5	62
93	Antiplatelet resistance--fact or myth?. <i>The American Heart Hospital Journal</i> , 2009 , 7, 50-7		1
92	Markers of Platelet Function. <i>Fundamental and Clinical Cardiology</i> , 2009 , 409-428		
91	Response variability and the role of platelet function testing. <i>Journal of Invasive Cardiology</i> , 2009 , 21, 172-8	0.7	9
90	The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 531-3	15.1	187
89	Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. <i>American Heart Journal</i> , 2008 , 155, 56-61	4.9	35
88	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. <i>Platelets</i> , 2008 , 19, 595-604	3.6	89
87	Diagnostics for aspirin resistance. <i>Molecular Diagnosis and Therapy</i> , 2008 , 12, 55-6	4.5	
86	Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 268-75	1	38

85	Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. <i>Southern Medical Journal</i> , 2008 , 101, 1203-8	0.6	56
84	Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 111-21	5	40
83	Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 128-35	3.3	1
82	Investigating the mechanisms of hyporesponse to antiplatelet approaches. <i>Clinical Cardiology</i> , 2008 , 31, 121-7	3.3	7
81	Assessing the current role of platelet function testing. <i>Clinical Cardiology</i> , 2008 , 31, 110-6	3.3	24
80	Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. <i>Clinical Cardiology</i> , 2008 , 31, 12-9	3.3	9
79	The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 117-20	3.3	27
78	Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. <i>Journal of Interventional Cardiology</i> , 2008 , 21, 283-89	1.8	2
77	The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. <i>Journal of Interventional Cardiology</i> , 2008 , 21 Suppl 1, S10-7	1.8	8
76	Abstract 4017: Reduced Anti-Platelet Response to Clopidogrel in Diabetic Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2008 , 118,	16.7	1
75	Abstract 5603: Oral Dosing of PRT060128, a Novel Direct-acting, Reversible P2Y ₁₂ Antagonist Overcomes High Platelet Reactivity in Patients Non-responsive to Clopidogrel Therapy. <i>Circulation</i> , 2008 , 118,	16.7	7
74	Prasugrel, a third generation thienopyridine and potent platelet inhibitor. <i>Current Opinion in Investigational Drugs</i> , 2008 , 9, 324-36		7
73	Antiplatelet treatment of cardiovascular disease: a translational research perspective 2008 , 118, 289-97		2
72	Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 657-66	15.1	328
71	Platelet function monitoring in patients with coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1822-34	15.1	384
70	Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y ₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1852-6	15.1	375
69	AZD6140. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 225-9	5.9	48
68	Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. <i>American Journal of Cardiology</i> , 2007 , 100, 18M-25M	3	25

67	The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. <i>Diabetes</i> , 2007 , 56, 3014-9	0.9	174
66	Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. <i>Platelets</i> , 2007 , 18, 414-23	3.6	42
65	Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. <i>Circulation</i> , 2007 , 115, 3156-64	16.7	315
64	Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 713-8	1	29
63	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. <i>Thrombosis Research</i> , 2007 , 119, 563-70	8.2	40
62	Clopidogrel resistance?. <i>Thrombosis Research</i> , 2007 , 120, 311-21	8.2	137
61	Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , 2007 , 121, 107-15	8.2	47
60	Resistance to antiplatelet drugs 2007 , 139-154		
59	Abstract 3472: The Prediction of Ischemic Events After Percutaneous Coronary Intervention by Platelet Reactivity to Adenosine Diphosphate: First Evidence for an Oral Antiplatelet Therapeutic Target Determined by an Ex Vivo Test of Platelet Function.. <i>Circulation</i> , 2007 , 116,	16.7	1
58	Antiplatelet therapy: current strategies and future trends. <i>Future Cardiology</i> , 2006 , 2, 343-66	1.3	25
57	Clopidogrel resistance: implications for coronary stenting. <i>Current Pharmaceutical Design</i> , 2006 , 12, 1261-9	3.9	18
56	Drug insight: Clopidogrel nonresponsiveness. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 387-95		89
55	Prasugrel. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1627-33	5.9	18
54	Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2186-91	15.1	71
53	Aspirin and clopidogrel resistance: consideration and management. <i>Journal of Interventional Cardiology</i> , 2006 , 19, 439-48	1.8	43
52	Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. <i>Pharmaceutical Research</i> , 2006 , 23, 2691-708	4.5	35
51	Clinical applications of antiplatelet therapy. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 130-46; quiz 148-9	3.9	2
50	The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7 Suppl 4, S20-8 ^{3.9}		10

49	Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2005 , 19, 11-8	2.1	16
48	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. <i>Thrombosis Research</i> , 2005 , 115, 89-94	8.2	123
47	The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1392-6	15.1	317
46	Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1705-9	15.1	258
45	Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1820-6	15.1	561
44	Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1827-32	15.1	461
43	The platelet-related effects of tenecteplase versus alteplase versus reteplase. <i>Blood Coagulation and Fibrinolysis</i> , 2005 , 16, 1-7	1	17
42	What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?. <i>Catheterization and Cardiovascular Interventions</i> , 2005 , 66, 597-8	2.7	18
41	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2027-45	4	54
40	Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. <i>Circulation</i> , 2005 , 111, 1153-9	16.7	312
39	Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. <i>Circulation</i> , 2004 , 109, 166-71	16.7	399
38	Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. <i>Platelets</i> , 2004 , 15, 95-9	3.6	41
37	Platelet activation in myocardial ischemic syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2004 , 2, 535-45	2.5	69
36	A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. <i>Platelets</i> , 2003 , 14, 481-3	3.6	11
35	The role of platelet receptors and adhesion molecules in coronary artery disease. <i>Coronary Artery Disease</i> , 2003 , 14, 65-79	1.4	30
34	Durability of platelet inhibition by clopidogrel. <i>American Journal of Cardiology</i> , 2003 , 91, 1123-5	3	110
33	The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. <i>Thrombosis Research</i> , 2003 , 112, 9-12	8.2	11
32	Platelet activation after stenting with heparin-coated versus noncoated stents. <i>American Heart Journal</i> , 2003 , 146, E10	4.9	10

31	Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. <i>American Heart Journal</i> , 2003 , 145, 239-47	4.9	106
30	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. <i>American Heart Journal</i> , 2003 , 145, 636-42	4.9	23
29	Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. <i>Circulation</i> , 2003 , 107, 2908-13	16.7	1280
28	Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. <i>American Journal of Cardiology</i> , 2002 , 90, 312-5	3	29
27	Correction of a saphenous vein graft to coronary vein anastomosis by selective retrograde coil-induced occlusion to arterialize the native vein. <i>Catheterization and Cardiovascular Interventions</i> , 2002 , 57, 541-4	2.7	1
26	Effect of eptifibatid for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 213-9	5.1	6
25	The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1199-204	15.1	226
24	Adhesion molecules, platelet activation, and cardiovascular risk. <i>American Heart Journal</i> , 2002 , 143, 196-8	4.9	10
23	Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?. <i>American Heart Journal</i> , 2002 , 143, 1068-75	4.9	28
22	Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. <i>Journal of Invasive Cardiology</i> , 2002 , 14, 584-9	0.7	21
21	Platelet function and fibrinolytic agents: two sides of a coin?. <i>Cardiology</i> , 2001 , 95, 55-60	1.6	6
20	Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. <i>American Journal of Cardiology</i> , 2001 , 87, 774-7, A7	3	14
19	Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2001 , 87, 1398-400	3	61
18	Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. <i>American Heart Journal</i> , 2001 , 142, 611-6	4.9	31
17	The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. <i>BioDrugs</i> , 2001 , 15, 395-404	7.9	5
16	Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 10, 15-22	5.1	19
15	Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 10, 217-20	5.1	17
14	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. <i>American Heart Journal</i> , 2000 , 139, 320-328	4.9	73

13	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. <i>American Heart Journal</i> , 2000 , 139, 320-8	4.9	12
12	Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 153-8	9.4	27
11	Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. <i>American Journal of Cardiology</i> , 1999 , 83, 1345-9	3	108
10	Clopidogrel: the future choice for preventing platelet activation during coronary stenting?. <i>Pharmacological Research</i> , 1999 , 40, 107-11	10.2	35
9	Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999 , 1, 243-9	12.3	34
8	Clinical utility of available methods for determining platelet function. <i>Cardiology</i> , 1999 , 92, 240-7	1.6	46
7	Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1466-73	15.1	145
6	Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. <i>American Heart Journal</i> , 1998 , 136, 398-405	4.9	48
5	Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. <i>Coronary Artery Disease</i> , 1998 , 9, 451-6	1.4	22
4	Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. <i>Pharmacology</i> , 1996 , 53, 79-86	2.3	6
3	Regional and Systemic Platelet Function Is Altered by Myocardial Ischemia-Reperfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 1995 , 1, 187-194	5.1	8
2	A canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. <i>Cardiology</i> , 1994 , 84, 1-8	1.6	3
1	Thienopyridine Response Variability and Resistance77-93		